Evofem Biosciences Reports First Year of Operating Profit

The latest announcement is out from Evofem Biosciences ( (EVFM) ).

On March 11, 2026, Evofem Biosciences reported financial results for the fourth quarter and full year 2025, marking its fifth consecutive year of net sales growth and its first year of positive operating income. Full-year net sales rose 4% to a record $20.2 million, driven mainly by Phexxi and a full year of Solosec sales, while fourth-quarter net sales jumped 35% to $9.6 million.

The company cut total operating expenses 38% to $16.8 million in 2025, aided by a settlement of trade payables and a one-time gain tied to the expiration of a royalty-bearing patent, which helped swing operating results from a $7.7 million loss in 2024 to $3.4 million of income in 2025. Net income attributable to common stockholders improved to $0.3 million for the year and $2.8 million for the fourth quarter, signaling a sharp turnaround, even as management continues to highlight capital constraints and nonrecurring gains that temper the durability of these improvements.

Since October 1, 2025, Evofem has pursued initiatives to significantly reduce manufacturing costs for both Phexxi and Solosec and has advanced regulatory steps in the UAE, including favorable pricing certificates for Phexxi and an ongoing review of Solosec. An NIH-funded Phase 4 study is also recruiting patients to compare the effectiveness and cost-effectiveness of single-dose Solosec versus multi-dose metronidazole for treating Trichomonas vaginalis, potentially strengthening the clinical and economic case for Solosec in the STI market.

The most recent analyst rating on (EVFM) stock is a Sell with a $0.01 price target. To see the full list of analyst forecasts on Evofem Biosciences stock, see the EVFM Stock Forecast page.

Spark’s Take on EVFM Stock

According to Spark, TipRanks’ AI Analyst, EVFM is a Neutral.

The score is held down primarily by weak financial fundamentals—declining revenue, ongoing net losses, negative free cash flow, and a highly pressured balance sheet with negative equity and sizeable debt. Valuation is difficult to support because the company is loss-making (negative P/E) and lacks a dividend yield, while technical analysis cannot be evaluated due to missing indicator data.

To see Spark’s full report on EVFM stock, click here.

More about Evofem Biosciences

Evofem Biosciences, Inc. is a San Diego-based pharmaceutical company focused on women’s sexual and reproductive health, commercializing two FDA-approved products. Its portfolio includes Phexxi, the first hormone-free, on-demand prescription contraceptive vaginal gel, and Solosec, a single-dose oral antibiotic for bacterial vaginosis and trichomoniasis.

The company operates in the U.S. sexual health market with an emphasis on innovative, convenient therapies that address unmet needs in contraception and sexually transmitted infection management. Evofem is also pursuing international opportunities, including potential expansion into the United Arab Emirates through ongoing regulatory reviews.

Average Trading Volume: 786,974

Technical Sentiment Signal: Sell

Current Market Cap: $1.13M

See more insights into EVFM stock on TipRanks’ Stock Analysis page.